Header Logo

Search Result Details

Back to Search Results
This page shows the details of why an item matched the keywords from your search.
Search Results
GARCIA-MANERO, GUILLERMO
One or more keywords matched the following items that are connected to GARCIA-MANERO, GUILLERMO
Item TypeName
Concept Maximum Tolerated Dose
Academic Article Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Academic Article Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.
Academic Article Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Academic Article A pilot pharmacokinetic study of oral azacitidine.
Academic Article Phase I study of epigenetic modulation with 5-azacytidine and valproic acid in patients with advanced cancers.
Academic Article Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.
Academic Article Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.
Academic Article Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Academic Article Phase I study of bortezomib in refractory or relapsed acute leukemias.
Academic Article Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Academic Article Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Academic Article Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia.
Academic Article Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome.
Academic Article Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
Academic Article A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
Academic Article A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Academic Article Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Academic Article A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias.
Academic Article Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies.
Academic Article Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study.
Academic Article Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias.
Academic Article A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ?30% blasts.
Academic Article Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies.
Academic Article Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial.
Academic Article Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia.
Academic Article Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.
Search Criteria
  • Maximum Tolerated Dose